Clinical trials for Hepatitis c virus infection investigate a range of treatment strategies and patient populations.

15 total trials for this combination

Showing top 10 of 15 trials

Trials

NCT ID	Title	Status	Phase
NCT02114177	Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis	COMPLETED	PHASE3
NCT02201940	Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection	COMPLETED	PHASE3
NCT02220998	Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection	COMPLETED	PHASE3
NCT02346721	Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection	COMPLETED	PHASE3
NCT02292706	A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection	TERMINATED	—
NCT02378961	Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection	COMPLETED	PHASE2
NCT02378935	Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection	COMPLETED	PHASE2
NCT02639247	Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor	COMPLETED	PHASE3
NCT02201953	Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection	COMPLETED	PHASE3
NCT02639338	Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis	COMPLETED	PHASE3

Related Pages

All Hepatitis c virus infection trials All trials in San Diego, United States